

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

Brilliant Violet 421(TM) anti-mouse CD3

RRID:AB_2562553

Type: Antibody

Proper Citation

BioLegend Cat# 100228, RRID:AB_2562553

Antibody Information

URL: http://antibodyregistry.org/AB_2562553

Proper Citation: BioLegend Cat# 100228, RRID:AB_2562553

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, ICC

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2562553

Vendor: BioLegend

Catalog Number: 100228

Alternative Catalog Numbers: 100227

Record Creation Time: 20250820T001813+0000

Record Last Update: 20250820T075506+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Yu X, et al. (2026) Bacterial vesicles from intratumoral *L. salivarius* enhance PD-1 blockade via FPR1-mediated macrophage polarization in gastric cancer. *Cell reports. Medicine*, 7(2), 102621.

Bosma DMT, et al. (2026) Requirements for development of T helper 1 and T follicular helper cells from a common precursor. *Cell reports*, 45(5), 117296.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8⁺ T-cell Immunity in the Tumor Microenvironment. *Cancer immunology research*, 14(5), 718.

Li Z, et al. (2026) Insufficient erythrocyte-derived S1P: A pathogenic driver and diagnostic biomarker for tumor progression. *iScience*, 29(4), 115216.

Park C, et al. (2026) A Rasa3-G β i signaling axis orchestrates B lymphocyte trafficking into and through lymphoid organs. *Cell reports*, 45(4), 117243.

Shamskhov EA, et al. (2026) Monocytic niches escape T cell surveillance and promote *Mycobacterium tuberculosis* persistence in lymph nodes. *Immunity*.

Silberstein E, et al. (2026) CCL signaling drives T Cell-Macrophage crosstalk in the mouse colon during chronic *Trypanosoma cruzi* infection. *iScience*, 29(7), 116611.

Liu S, et al. (2026) γ -hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. *Cell*, 189(6), 1701.

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. *Cancer cell*, 43(5), 823.

Zeng Q, et al. (2025) Gut microbiota-driven pathogenic Th17 cells mediated autoimmune epididymo-orchitis in a mouse model of colitis. *iScience*, 28(5), 112508.

Wei H, et al. (2025) AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. *Cell metabolism*, 37(5), 1103.

Mout R, et al. (2025) Design of soluble Notch agonists that drive T cell development and boost immunity. *Cell*.

Guruprasad P, et al. (2025) Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. *Nature protocols*.

Zhong Y, et al. (2025) Photoconverted cells allow rapid assessment of vaccine adjuvant potency in mice. *iScience*, 28(7), 112774.

Mayerhofer C, et al. (2025) OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis. *Cell metabolism*.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. *Cell*, 188(26), 7591.

Sonehara K, et al. (2025) Whole-genome sequencing reveals rare and structural variants contributing to psoriasis and identifies CERCAM as a risk gene. *Cell genomics*, 100978.

Wofford W, et al. (2024) Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response. *Cell reports*, 43(8), 114532.

Mei D, et al. (2024) Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models. *Journal for immunotherapy of cancer*, 12(9).

Shapir Itai Y, et al. (2024) Bispecific dendritic-T cell engager potentiates anti-tumor immunity. *Cell*, 187(2), 375.